Web2 days ago · The first patient has been dosed in a phase 1/2 clinical study assessing the immunotherapy KVA12123 alone and with Keytruda (pembrolizumab) for the treatment of … WebApr 13, 2024 · Immunotherapy has shown promising results in multiple cancer types, including melanoma, ... In this study, the Princess Margaret Cancer Centre researchers analyzed plasma samples from 81 patients with advanced solid tumors who were being treated with investigational immunotherapy agents in 37 different Phase I/II trials.
New type of genetically-engineered T-cell may destroy solid …
WebApr 8, 2024 · Focal ablation technologies are routinely used in the clinical management of inoperable solid tumors but they often result in incomplete ablations leading to high recurrence rates. Adjuvant therapies, capable of safely eliminating residual tumor cells, are therefore of great clinical interest. Interleukin-12 (IL-12) is a potent antitumor cytokine that … WebApr 8, 2024 · Focal ablation technologies are routinely used in the clinical management of inoperable solid tumors but they often result in incomplete ablations leading to high … how to start medical business
DGAP-News: VAXIMM Initiates Phase I/II Trial with VXM01 Oral T …
Web1 day ago · VISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated by end of ... WebGiven the capacity for CAR T-cells to induce high response rates and exert durable efficacy in the various settings noted above, expanding the utility of cellular immunotherapy in … WebNov 14, 2024 · HPN601 is the first conditionally active T cell engager based on the ProTriTAC™ platform. EpCAM is expressed in a broad range of solid tumors, potentially enabling HPN601 to address multiple indications with high unmet medical need. Harpoon expects to be ready to file an IND in the first half of 2024 to enable a Phase 1 dose … how to start mediation process